Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation

Type of Cancer
Neuro-Oncology

Sponsor
Alliance

Protocol Number
A071102

To Learn More Call
201-510-0910

Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations

Type of Cancer
Neuro-Oncology

Site
Hackensack

Sponsor
Alliance

Protocol Number
A071401

To Learn More Call
201-510-0910

A Phase 3, Randomized, Double blind, Placebo controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP 196) in Subjects with Previously Untreated Mantle Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Acerta

Protocol Number
Acerta ACE-LY-308

To Learn More Call
201-510-0910

Expanded Access (Compassionate Use) Treatment Protocol: Rindopepimut (CDX-110)

Sponsor
Celldex

Protocol Number
Celldex Compassionate Use CDX 110-05

To Learn More Call
201-510-0910

Pilot Study of NovoTTF in Conjunction with Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma

Sponsor
HackensackUMC

Protocol Number
HackensackUMC IST NovoChemoRads

To Learn More Call
201-510-0910

A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma

Sponsor
Tocagen

Protocol Number
Tocagen Tg 511-15-01

To Learn More Call
201-510-0910

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab Versus Bevacizumab Alone in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy

Type of Cancer
Neuro-Oncology

Sponsor
Boston Biomedical

Protocol Number
BBI-DSP7888-201G

To Learn More Call
201-510-0910

A Randomized Phase 2 Single Blind Study of Temozolomide plus Radiation Therapy combined with Nivolumab or Placebo in Newly Diagnosed Adult Subjects with MGMT-Methylated (tumor O6 methylguanine DNA methyltransferase) Glioblastoma

Type of Cancer
Neuro-Oncology

Sponsor
Bristol-Myers Squibb

Protocol Number
CA209-548

To Learn More Call
201-510-0910

Open-label, Randomized, Controlled, Phase 3 Safety and Efficacy Study of Trans Sodium Crocetinate (TSC) with Radiation Therapy and Temozolomide in Newly Diagnosed Glioblastoma (GBM) Biopsy-Only Subjects

Type of Cancer
Neuro-Oncology

Sponsor
Diffusion Pharma

Protocol Number
100-206

To Learn More Call
201-510-0910

A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation